NL-OMON42816已完成3 期
Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostate cancer - 0080CA002
ovalon S.A.0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Males aged 18 years (inclusive) or above;2. Histologically confirmed prostate adenocarcinoma and indicated for androgen deprivation therapy (ADT). Previous prostatectomy and/or prostate radiotherapy is allowed.;3. Good physical and mental health as judged by the Investigator determined by medical history, physical examination, clinical laboratory and vital signs;4. Willing to give informed consent in writing;5. Willing and able to attend the scheduled study visits and to comply with the study procedures;6. Baseline testosterone level > 250 ng/dL;7. PSA level >= 4 ng/mL;Exception: for patients who have had previous prostatectomy and/or prostate radiotherapy, all PSA levels are allowed.;8. Life expectancy > 1 year;9. Body Mass Index between 18.5 and 35 kg/m2 inclusive;10. ECOG score of <=2
排除标准
- •1. Previous or current hormonal management of prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor agonists, GnRH receptor antagonists, anti-androgens, estrogens) within 6 months prior to the Screening visit;2. Scheduled for prostatectomy or radiotherapy during study period;3. ALT (SGOT) or AST (SGPT) >=2x upper limit of normal (ULN) ;4. moderate (stage 3B) or severe (stage 4 and 5) chronic kidney disease with an eGFR <45 mL/min/1,73m2;5. Has received an investigational drug within the last 28 days before the screening visit or longer if considered by the Investigator to possibly influencing the outcome of this trial ;6. History or presence of any malignancy other than treated squamous cell/basal cell carcinoma of the skin within the last five years;7. Have an unstable medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease), or malignancy that could confound interpretation of the study at Investigator discretion;8. History of severe uncontrolled asthma, anaphylactic reactions, or severe urticarial and/or angioedema, and particularly, history of hypersensitivity towards any components of the study drug;9. Other abnormal laboratory results which in the judgment of the Investigator would affect the patient's health or the outcome of the trial;10. Has an intellectual incapacity or language barrier precluding adequate understanding or co-operation
研究者
相似试验
进行中（未招募）
1 期
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.Prostate cancerEUCTR2013-000799-14-BEovalon S. A.142
进行中（未招募）
1 期
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.Prostate cancerEUCTR2019-000593-32-DEovalon S.A.142
进行中（未招募）
1 期
An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.MedDRA version: 18.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancerEUCTR2013-000799-14-NLovalon S. A.142
进行中（未招募）
1 期
Phase III, open-label, multi-centre study to investigate the movement, effect and safety of Zoreline 3.6 mg goserelin implant (Novalon) injected under skin, in women with confirmed endometriosisMedDRA version: 19.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2013-000798-59-HUovalon S.A142
未知
3 期
Phase 3, multicenter, open-label study to evaluate the safety and efficacy of long-term administration of TAK-085 to the patients with hypertriglyceridemiaHypertriglyceridemiaJPRN-jRCT2080220904Takeda Pharmaceutical Company Limited